For example, HNSCC therapy has undergone a significant change in recent years with the development of precision medicines, such as bevacizumab, against vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) based on the special gene expression signature, and prognostic outcomes in HNSCC (3–5). This evidence concerns the gene VEGFA and head and neck squamous cell carcinoma.